TrialX
Image

Safety and Effectiveness Assessment of the MakAir Artificial Ventilator

Safety and Effectiveness Assessment of the MakAir Artificial Ventilator

Recruiting
18 years and older
All
Phase N/A

Overview

The objective of our study is to carry out an evaluation of the safety and the effectiveness of the use of the MakAir respirator as useful supplement in situation of shortage of technical devices of assistance to the mechanical invasive ventilation, related to COVID-19 through a protocol in 3 successive sequences.

Eligibility

Inclusion Criteria:

Sequence 1 :

  • Patient for whom a certificate has been signed by a support person / family member / close relative independent of the sponsor.
  • Adult
  • Non-hypoxemic patient (PaO2 / FiO2> 300)
  • Patient requiring invasive mechanical ventilation> 24 hours
  • Stabilized patient, i.e. not needing an increase in oxygenation for at least 6 hours

Sequence 2 :

  • Patient for whom a certificate of consent has been signed by a support person / family member / close relative independent of the sponsor.
  • Adult
  • Patient with mild to moderate Acute respiratory distress syndrome (300> Pa02 / FiO2> 100)
  • Patient requiring invasive mechanical ventilation> 3 days
  • Stabilized patient, i.e. having not required an increase in oxygenation for at least 6 hours

Sequence3 :

  • Patient for whom a certificate of consent has been signed by a support person / family member / close relative independent of the sponsor or waiver due to life-threatening emergency.
  • Adult
  • Patient with mild to moderate Acute respiratory distress syndrome (PaO2 / FiO2> 100) or without Acute respiratory distress syndrome
  • Patient requiring invasive mechanical ventilation for any duration
  • Situation of shortage among centers investigating technical devices for invasive ventilation to treat all patients

Exclusion Criteria:

Sequence 1 and sequence 2:

  • Patient positive or showing signs of Covid-19 infection
  • Tracheotomized patient
  • History of pulmonary emphysema or severe to moderate chronic obstructive pulmonary disease
  • Patient in recovery and withdrawal phase of ventilatory assistance
  • Pneumothorax or pneumomediastinum
  • Hemodynamic instability
  • Intracranial hypertension
  • Pregnant woman (A urine or blood pregnancy test must be performed for women of childbearing age)
  • Major protected (guardianship, curatorship and under the protection of justice)
  • Lack of affiliation to the French social security system
  • Participation in another interventional clinical trial

Sequence3 :

  • Tracheotomized patient
  • History of pulmonary emphysema or severe to moderate moderate chronic obstructive pulmonary disease
  • Patient in recovery and withdrawal phase of ventilatory assistance
  • Pneumothorax or pneumomediastinum
  • Hemodynamic instability
  • Intracranial hypertension
  • Pregnant woman (A urine or blood pregnancy test must be performed for women of childbearing age)
  • Major protected (guardianship, curatorship and under the protection of justice)
  • Lack of affiliation to the French social security system
  • Participation in another interventional clinical trial on mechanical ventilation

Study details
    Pulmonary Disease
    ADULT RESPIRATORY DISTRESS SYNDROME

NCT04475185

Nantes University Hospital

16 February 2024

Step 1 Get in touch with the nearest study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team


Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.